Opus Genetics (IRD) Other Operating Expenses (2010 - 2024)
Opus Genetics (IRD) reported Other Operating Expenses of $28.0 million for Q4 2024, up 234.29% on a QoQ basis from $8.4 million in Q4 2020.
Opus Genetics (IRD) has 7 years of Other Operating Expenses data on file, last reported at $28.0 million in Q4 2024.
- Quarterly Other Operating Expenses changed N/A year-over-year to $28.0 million in Q4 2024, while the trailing twelve-month figure through Sep 2025 was $28.0 million (changed N/A YoY) and the FY2024 annual result came in at $28.0 million, changed N/A from the prior year.
- Other Operating Expenses grew to $28.0 million in Q4 2024 per IRD's latest filing, from $8.4 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $28.0 million in Q4 2024 and bottomed at $2.1 million in Q1 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 28.00 Mn |
| Dec 31, 2020 | 8.38 Mn |
| Mar 31, 2020 | 2.13 Mn |
| Sep 30, 2014 | -3,744.00 |
| Jun 30, 2014 | -9,630.00 |
| Mar 31, 2014 | -9,044.00 |
| Dec 31, 2013 | -395,039.00 |
| Sep 30, 2013 | 100,199.00 |
| Jun 30, 2013 | 121,216.00 |
| Mar 31, 2013 | 136,491.00 |
| Dec 31, 2012 | 128,566.00 |
| Sep 30, 2012 | 122,571.00 |
| Jun 30, 2012 | 77,373.00 |
| Mar 31, 2012 | 102,589.00 |
| Dec 31, 2011 | 171,864.00 |
| Sep 30, 2011 | 198,424.00 |
| Jun 30, 2011 | 103,225.00 |
| Mar 31, 2011 | 86,641.00 |
| Dec 31, 2010 | 107,652.00 |
| Sep 30, 2010 | 134,810.00 |
| Jun 30, 2010 | 73,841.00 |